"Designing Growth Strategies is in our DNA"

Multiple Sclerosis Drugs Market Size, Share & Industry Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2024-2032

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI100386

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Multiple Sclerosis - For Key Countries/Regions, 2022/2023
    2. Regulatory Scenario - For Key Countries/Regions
    3. Patent Snapshot, By Key Players
    4. Pipeline Analysis & R&D Investments
    5. New Product Launches, By Key Players
    6. Key Industry Developments - Mergers, Acquisitions and Partnerships
    7. Overview: Multiple Sclerosis Treatment Cost
    8. Impact of COVID-19 on the Market
  5. Global Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
  7. Europe Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Germany
      2. U.K.
      3. France
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. China
      2. India
      3. Japan
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. South Africa
      2. GCC
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Global Market Share Analysis (2023)
    2. Company Profiles
      1. Biogen
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Teva Pharmaceutical Industries Ltd.
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Merck KGaA
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Sanofi
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Novartis AG
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. F. Hoffmann-La Roche Ltd.
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Pfizer Inc.
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Bristol-Myers Squibb Company
        1. Overview
        2. Products & Services
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Figure 1: Global Multiple Sclerosis Drugs Market Revenue Breakdown (USD billion, %) by Region, 2023 & 2032

Figure 2: Global Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2023 & 2032

Figure 3: Global Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2023 & 2032

Figure 4: Global Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2023 & 2032

Figure 5: Global Multiple Sclerosis Drugs Market Value (USD billion), by Region, 2023 & 2032

Figure 6: North America Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 7: North America Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2023

Figure 8: North America Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2023 & 2032

Figure 9: North America Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2023

Figure 10: North America Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 11: North America Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2023

Figure 12: North America Multiple Sclerosis Drugs Market Value (USD billion), By Country, 2023 & 2032

Figure 13: North America Multiple Sclerosis Drugs Market Value Share (%), By Country, 2023

Figure 14: Europe Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 15: Europe Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2023

Figure 16: Europe Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2023 & 2032

Figure 17: Europe Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2023

Figure 18: Europe Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 19: Europe Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2023

Figure 20: Europe Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2023 & 2032

Figure 21: Europe Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2023

Figure 22: Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 23: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2023

Figure 24: Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2023 & 2032

Figure 25: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2023

Figure 26: Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 27: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2023

Figure 28: Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2023 & 2032

Figure 29: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2023

Figure 30: Latin America Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 31: Latin America Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2023

Figure 32: Latin America Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2023 & 2032

Figure 33: Latin America Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2023

Figure 34: Latin America Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 35: Latin America Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2023

Figure 36: Latin America Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2023 & 2032

Figure 37: Latin America Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2023

Figure 38: Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2023 & 2032

Figure 39: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2023

Figure 40: Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2023 & 2032

Figure 41: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2023

Figure 52: Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2023 & 2032

Figure 43: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2023

Figure 44: Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2023 & 2032

Figure 45: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2023

Figure 46: Global Multiple Sclerosis Drugs Market Share (%), By Company, 2023

Table 1: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 2: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 3: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2019–2032

Table 4: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 5: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Region, 2019–2032

Table 6: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 7: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 8: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2019–2032

Table 9: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 10: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country, 2019–2032

Table 11: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 12: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 13: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2019–2032

Table 14: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 15: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019–2032

Table 16: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 17: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 18: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2019–2032

Table 19: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 20: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019–2032

Table 21: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 22: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 23: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2019–2032

Table 24: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 25: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019–2032

Table 26: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2019–2032

Table 27: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 28: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2019–2032

Table 29: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 30: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019–2032

Multiple Sclerosis Drugs Market Size, Share and Global Industry Trend Forecast till 2032
  • 2019-2032
  • 2023
  • 2019-2022
  • 165
Consulting Services
    How will you benefit from our consulting services ?